[go: up one dir, main page]

PL3294323T3 - Wirus związany z adenowirusem do terapeutycznego dostarczania do ośrodkowego układu nerwowego - Google Patents

Wirus związany z adenowirusem do terapeutycznego dostarczania do ośrodkowego układu nerwowego

Info

Publication number
PL3294323T3
PL3294323T3 PL16797013T PL16797013T PL3294323T3 PL 3294323 T3 PL3294323 T3 PL 3294323T3 PL 16797013 T PL16797013 T PL 16797013T PL 16797013 T PL16797013 T PL 16797013T PL 3294323 T3 PL3294323 T3 PL 3294323T3
Authority
PL
Poland
Prior art keywords
nervous system
central nervous
therapeutic delivery
adenovirus virus
adenovirus
Prior art date
Application number
PL16797013T
Other languages
English (en)
Inventor
R. Scott Mcivor
Lalitha R. BELUR
Karen Kozarsky
Original Assignee
Regenxbio Inc.
Regents Of The University Of Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57320277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3294323(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regenxbio Inc., Regents Of The University Of Minnesota filed Critical Regenxbio Inc.
Publication of PL3294323T3 publication Critical patent/PL3294323T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076L-Iduronidase (3.2.1.76)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL16797013T 2015-05-15 2016-05-13 Wirus związany z adenowirusem do terapeutycznego dostarczania do ośrodkowego układu nerwowego PL3294323T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562162174P 2015-05-15 2015-05-15
US201562252055P 2015-11-06 2015-11-06
US201662301980P 2016-03-01 2016-03-01
US201662331156P 2016-05-03 2016-05-03
EP16797013.6A EP3294323B1 (en) 2015-05-15 2016-05-13 Adeno-associated virus for therapeutic delivery to central nervous system
PCT/US2016/032392 WO2016187017A1 (en) 2015-05-15 2016-05-13 Adeno-associated for therapeutic delivery to central nervous system

Publications (1)

Publication Number Publication Date
PL3294323T3 true PL3294323T3 (pl) 2022-06-20

Family

ID=57320277

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16797013T PL3294323T3 (pl) 2015-05-15 2016-05-13 Wirus związany z adenowirusem do terapeutycznego dostarczania do ośrodkowego układu nerwowego

Country Status (23)

Country Link
US (5) US20180289839A1 (pl)
EP (2) EP3294323B1 (pl)
JP (4) JP2018515615A (pl)
KR (3) KR20220082100A (pl)
CN (1) CN108367055A (pl)
AU (2) AU2016263119B2 (pl)
BR (1) BR112017024519A2 (pl)
CA (1) CA2986252A1 (pl)
CY (1) CY1125229T1 (pl)
DK (1) DK3294323T3 (pl)
ES (1) ES2901766T3 (pl)
HK (1) HK1256341A1 (pl)
HR (1) HRP20220050T1 (pl)
HU (1) HUE057795T2 (pl)
LT (1) LT3294323T (pl)
MX (2) MX2017014443A (pl)
PL (1) PL3294323T3 (pl)
PT (1) PT3294323T (pl)
RS (1) RS63927B1 (pl)
RU (1) RU2751952C2 (pl)
SI (1) SI3294323T1 (pl)
SM (1) SMT202200022T1 (pl)
WO (1) WO2016187017A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2971039B1 (en) 2013-03-14 2020-01-01 Immusoft Corporation Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors
EP3747998B1 (en) 2013-03-15 2024-07-24 The Trustees of the University of Pennsylvania Compositions for treating mpsi
RU2692251C2 (ru) * 2013-05-15 2019-06-24 Риджентс Оф Зэ Юниверсити Оф Миннесота Опосредованный аденоассоциированным вирусом перенос генов в центральную нервную систему
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
WO2016187017A1 (en) 2015-05-15 2016-11-24 Mcivor R Scott Adeno-associated for therapeutic delivery to central nervous system
US10973929B2 (en) 2016-02-03 2021-04-13 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type I
WO2017181113A1 (en) * 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsyvania Gene therapy for treating mucopolysaccharidosis type ii
KR20190086503A (ko) * 2016-11-15 2019-07-22 리젠츠 오브 더 유니버시티 오브 미네소타 Mpsi 및 mpsii에서의 신경계 기능 및 다른 신경계 장애를 개선하는 방법
WO2018191666A1 (en) 2017-04-14 2018-10-18 Regenxbio Inc. Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 sulfatase (ids) produced by human neural or glial cells
CN110709090A (zh) * 2017-04-27 2020-01-17 益缪索夫特公司 用于在体内递送治疗剂的b细胞及其剂量
JP2020526514A (ja) * 2017-07-06 2020-08-31 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ムコ多糖症i型を治療するための遺伝子治療
TWI835747B (zh) 2017-09-22 2024-03-21 賓州大學委員會 用於治療黏多醣病 ii 型之基因治療
CN112501208A (zh) 2017-10-03 2021-03-16 普利维尔治疗公司 用于溶酶体障碍的基因疗法
BR112020006661A2 (pt) 2017-10-03 2020-10-13 Prevail Therapeutics, Inc. terapias de genes para distúrbios lipossomais
US11802294B2 (en) 2017-10-03 2023-10-31 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
CA3083761A1 (en) 2017-11-30 2019-06-06 The Trustees Of The University Of Pennsylvania Gene therapy for mucopolysaccharidosis iiib
WO2019199841A1 (en) * 2018-04-09 2019-10-17 Cure Ahc, Inc. Aav-mediated delivery of atp1a3 genes to central nervous system
IL280198B1 (en) * 2018-07-18 2025-09-01 Regenxbio Inc Treatment of mucopolysaccharidosis I with fully glycosylated human iduronidase-alpha-L (idus)
MX2021010266A (es) * 2019-02-26 2021-09-23 Univ Pennsylvania Composiciones utiles en el tratamiento de la enfermedad de krabbe.
CN113811359A (zh) * 2019-03-22 2021-12-17 拉什大学医学中心 用于溶酶体贮积症的经鼻基因递送和口服肉桂酸、油酰胺或吉非贝齐的组合
WO2020210713A1 (en) 2019-04-10 2020-10-15 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
WO2020227166A1 (en) * 2019-05-03 2020-11-12 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of metachromatic leukodystrophy
MX2021015076A (es) * 2019-06-10 2022-06-02 Homology Medicines Inc Composiciones de virus adeno-asociados para transferencia del gen de la enzima lisosomal arilsulfatasa-a (arsa) y metodos de uso de las mismas.
CA3155154A1 (en) * 2019-10-23 2021-04-29 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
EP4072595A1 (en) 2019-12-10 2022-10-19 Takeda Pharmaceutical Company Limited Adeno associated virus vectors for the treatment of hunter disease
JP2023537903A (ja) * 2020-08-10 2023-09-06 プリベイル セラピューティクス,インコーポレーテッド リソソーム障害に対する遺伝子療法
CN117642173A (zh) * 2020-12-07 2024-03-01 华东理工大学 用于诱导对基因递送靶媒剂的免疫耐受性的方法和试剂盒
EP4284335A1 (en) 2021-02-01 2023-12-06 RegenxBio Inc. Gene therapy for neuronal ceroid lipofuscinoses
CA3209611A1 (en) 2021-02-10 2022-08-18 Regenxbio Inc. Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
US20240366789A1 (en) * 2021-04-01 2024-11-07 The University Of North Carolina At Chapel Hill Aav-ids vectors for treatment of mucopolysaccharidosis ii

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
EP0733103B1 (en) 1993-11-09 2004-03-03 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
ATE272123T1 (de) 1993-11-09 2004-08-15 Ohio Med College Stabile zellinie, die in der lage ist, das replikationsgen des adenoassoziertenvirus zu exprimieren
EP0796339A1 (en) 1994-12-06 1997-09-24 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
US5656785A (en) 1995-08-07 1997-08-12 The Charles Stark Draper Laboratory, Inc. Micromechanical contact load force sensor for sensing magnitude and distribution of loads and tool employing micromechanical contact load force sensor
AU5445998A (en) 1996-11-19 1998-06-10 Surgx Corporation A transient voltage protection device and method of making same
CA2270285A1 (en) 1996-12-18 1998-06-25 Targeted Genetics Corporation Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors
EP1915986A1 (en) 2006-10-23 2008-04-30 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Lipid growth factor formulations
ES2634118T3 (es) * 2009-02-11 2017-09-26 The University Of North Carolina At Chapel Hill Vectores de virus modificados y métodos para fabricar y utilizar los mismos
EP2394667A1 (en) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
HRP20191924T1 (hr) * 2010-06-25 2020-01-10 Shire Human Genetic Therapies, Inc. Postupci i sastavi za isporuku iduronat-2-sulfataze u cns
WO2012135857A1 (en) * 2011-03-31 2012-10-04 University Of Iowa Research Foundation Methods and compositions for treating brain diseases
US8609088B2 (en) * 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
US20130039888A1 (en) * 2011-06-08 2013-02-14 Nationwide Children's Hospital Inc. Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
CA2852955C (en) * 2011-10-27 2021-02-16 Sangamo Biosciences, Inc. Methods and compositions for modification of the hprt locus
RU2692251C2 (ru) * 2013-05-15 2019-06-24 Риджентс Оф Зэ Юниверсити Оф Миннесота Опосредованный аденоассоциированным вирусом перенос генов в центральную нервную систему
MX373332B (es) * 2013-07-26 2020-05-21 Univ Iowa Res Found UNA PARTÍCULA rAAV Y UN AGENTE DE INMUNOSUPRESIÓN PARA USARSE EN EL TRATAMIENTO DE ENFERMEDADES.
WO2016187017A1 (en) * 2015-05-15 2016-11-24 Mcivor R Scott Adeno-associated for therapeutic delivery to central nervous system
KR20190086503A (ko) * 2016-11-15 2019-07-22 리젠츠 오브 더 유니버시티 오브 미네소타 Mpsi 및 mpsii에서의 신경계 기능 및 다른 신경계 장애를 개선하는 방법
CA3209611A1 (en) * 2021-02-10 2022-08-18 Regenxbio Inc. Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)

Also Published As

Publication number Publication date
JP2018515615A (ja) 2018-06-14
BR112017024519A2 (en) 2018-07-24
ES2901766T3 (es) 2022-03-23
CY1125229T1 (el) 2023-06-09
EP3294323B1 (en) 2021-10-13
KR20250150167A (ko) 2025-10-17
MX2022012524A (es) 2022-11-16
US20180071373A1 (en) 2018-03-15
CA2986252A1 (en) 2016-11-24
KR20180118508A (ko) 2018-10-31
US20210369871A1 (en) 2021-12-02
LT3294323T (lt) 2022-02-25
HUE057795T2 (hu) 2022-06-28
AU2016263119A1 (en) 2018-01-18
HK1256341A1 (zh) 2019-09-20
US20220211875A1 (en) 2022-07-07
MX2017014443A (es) 2018-08-01
JP2024147704A (ja) 2024-10-16
US20230226225A1 (en) 2023-07-20
WO2016187017A1 (en) 2016-11-24
JP2021167332A (ja) 2021-10-21
SMT202200022T1 (it) 2022-03-21
RU2017143640A (ru) 2019-06-17
HK1252871A1 (en) 2019-06-06
US20180289839A1 (en) 2018-10-11
KR102406615B1 (ko) 2022-06-08
HRP20220050T1 (hr) 2022-10-14
AU2016263119B2 (en) 2021-08-12
RU2751952C2 (ru) 2021-07-21
SI3294323T1 (sl) 2022-06-30
DK3294323T3 (da) 2022-01-10
EP4000631A1 (en) 2022-05-25
JP2022137261A (ja) 2022-09-21
AU2021266344B2 (en) 2024-08-22
CN108367055A (zh) 2018-08-03
PT3294323T (pt) 2022-01-06
AU2021266344A1 (en) 2021-12-09
RS63927B1 (sr) 2023-02-28
RU2020125073A (ru) 2020-08-27
RU2017143640A3 (pl) 2019-11-22
EP3294323A4 (en) 2019-01-16
KR20220082100A (ko) 2022-06-16
EP3294323A1 (en) 2018-03-21

Similar Documents

Publication Publication Date Title
PL3294323T3 (pl) Wirus związany z adenowirusem do terapeutycznego dostarczania do ośrodkowego układu nerwowego
DK3328880T3 (da) Terapeutiske midler
DK3265421T3 (da) Doseringssystem
IL253719A0 (en) Pharmaceutical compositions for combination therapy
EP3314027A4 (en) THERAPEUTIC OLIGONUCLEOTIDES
EP3368656A4 (en) TARGETED CANCER THERAPY
DK3139986T3 (da) System til administration af terapeutisk gas
LT3253865T (lt) Metodai, skirti sustiprinti terapinių imuninių ląstelių veiksmingumą
MA40764A (fr) Agent thérapeutique induisant une cytotoxicité
DK3262066T4 (da) Genterapi
GB201500463D0 (en) Therapeutic molecules
DK3258938T3 (da) Phenothiazinanaloger som mitokondrie terapeutiske midler
GB201500461D0 (en) Therapeutic molecules
DK3199161T3 (da) Farmaceutisk præparat
EP3389589C0 (en) MEDICAL DELIVERY DEVICE
DK3310800T3 (da) Leveringssystem til styret lægemiddelfrigivelse
DK3363428T3 (da) Perfusionsdoseringsform
EP3246047C0 (en) COMBINATION MEDICATION
DK3288955T3 (da) Bortezomib-baseret afgivelsessystem
EP3244868C0 (en) DRUG DELIVERY DEVICES
DK3393478T3 (da) Kombinationsterapi
EP3362091A4 (en) COMBINATION THERAPY
DK3310379T3 (da) Vegfr-2-targeterende dna-vaccine til kombinationsterapi
DK3329004T3 (da) Terapeutiske oligonukleotider
EP4233950C0 (en) NASAL ADMINISTRATION